Unicycive Therapeutics Inc UNCY
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-17 |
| Shares Out. | 26,700,000 |
| Website | unicycive.com/ ↗ |
| Phone | 16503840642 |
| Employees | 22 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$1.7M |
| Free Cash Flow | -$27.8M |
| Total Assets | $72.0M |
| Total Liabilities | $18.8M |
| Equity | $53.3M |
About Unicycive Therapeutics Inc
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Unicycive Therapeutics Inc is a publicly traded company under the ticker symbol UNCY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-09-01)